Bilateral optic neuropathy associated with lorlatinib monotherapy for ALK-positive metastatic lung adenocarcinoma
Open Access
- 25 April 2024
- journal article
- case report
- Published by Elsevier in American Journal of Ophthalmology Case Reports
- Vol. 34, 102063
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN studyThe Lancet Respiratory Medicine, 2022
- Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients With ALK-Positive Advanced Non–Small-Cell Lung Cancer From the Phase III CROWN StudyJournal of Clinical Oncology, 2022
- Postmarketing safety of anaplastic lymphoma kinase (ALK) inhibitors: an analysis of the FDA Adverse Event Reporting System (FAERS)ESMO Open, 2021
- First-Line Lorlatinib or Crizotinib in Advanced ALK -Positive Lung CancerNew England Journal of Medicine, 2020
- Safety issues with the ALK inhibitors in the treatment of NSCLC: A systematic reviewCritical Reviews in Oncology/Hematology, 2019
- Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trialThe Lancet Oncology, 2017
- Ocular Toxicity of Tyrosine Kinase InhibitorsOncology Nursing Forum, 2016
- Optic Neuropathy and Blindness Associated With Crizotinib for Non–Small-Cell Lung Cancer With EML4-ALK TranslocationJournal of Clinical Oncology, 2015
- First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung CancerNew England Journal of Medicine, 2014
- Crizotinib Reduces the Rate of Dark Adaptation in the Rat Retina Independent of ALK InhibitionToxicological Sciences, 2014